Evaluation of S-600918 in Adults With Refractory Chronic Cough

Phase 2 Completed 406 enrolled Shionogi

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.

Timeline

Start: 2020-02-13
Primary completion: 2020-12-08
Completion: 2020-12-28

Publications

McGarvey L, Smith JA, Morice A, Birring SS, Chung KF, Dicpinigaitis PV, Niimi A, Benninger MS, Sher M, Matsunaga Y, Miyazaki S, Machida M, Ishihara H, Mahmood A, Gomez JC. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. Lung. 2023 Feb;201(1):25-35. doi: 10.1007/s00408-022-00592-5. Epub 2022 Dec 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	S-600918	Unknown	50 mg	Oral
Subject	S-600918	Unknown	150 mg	Oral
Subject	S-600918	Unknown	300 mg	Oral

Indications

No indication recorded.